Clovis rallies on new CO-1686 data

|About: Clovis Oncology (CLVS)|By:, SA News Editor

Clovis Oncology (CLVS +0.5%) rises after updating investors on its EGFR inhibitor CO-1686.

CLVS says partial responses (RECIST) were observed in nine T790M positive patients (67% objective response rate). At ASCO, only four T790M positive patients were evaluable.

Eight of those patients (89%) "experienced tumor shrinkage greater than 10%." (PR)